Purpose: In the previous LNH87-2 study, consolidative highdose therapy followed by stem cell transplantation (HDT) improved disease-free survival, as well as survival for patients (pts) presenting with two or three factors of the age-adjusted international prognostic index (Aa-IPI) in first complete remission (CR). In order to improve further the outcome of such patients, we conducted a pilot study of consolidative tandem autotranplant.
Introduction
After almost twenty years of clinical trial research on high-dose therapy followed by stem cell transplantation (HDT) in the setting of aggressive non-Hodgkin's lymphoma, it appears that such an approach is now accepted to be applicable to sensitive-relapsed patients [1, 2] . In higher risk patients (presenting with 2 or 3 factors of the Aa-IPI), HDT used as frontline therapy remains the subject of ongoing studies, although completed trials have provided some evidence that this procedure benefits such patients [3] [4] [5] [6] . These patients represent about half of all cases of aggressive lymphoma and, with presently available conventional chemotherapy regimens, about 40% of them are disease-free at five years and can eventually be cured [7] . From 1987, the Groupe d'Etudes des Lymphomes de l'Adulte (GELA) conducted two consecutive randomized studies to explore the potential benefit of HDT for patients with aggressive lymphoma and adverse prognostic factors. In the LNH87-2 study, we observed that a consolidative CBV (cyclophosphamide, carmustine, VP16) regimen improved both disease-free survival and survival over sequential chemotherapy in patients presenting with at least two adverse prognostic factors of the Aa-IPI, if they previously achieved complete remission (CR) after ACVBP induction treatment [5, 6] . However, in this study the CR rate was only 61%, a factor leading us to design the subsequent LNH93-3 study in which, with the aim of increasing the rate and quality of response, early HDT was incorporated in an abbreviated induction phase. Since this approach failed [8, Gisselbrecht et al.,  manuscript submitted], we decided to explore the benefit of consolidative tandem transplant procedure in good-responder patients in order to decrease the relapse rate. Indeed due to the widespread use of hematopoietic growth factors and of peripheral blood progenitor cells, new conditioning regimens have been designed on the basis of the theoretical principles of cancer chemotherapy in order to prevent the emergence of secondary resistance. Tandem transplant regimens have been proposed as new strategies with the aim to increase dose size and duration of drug exposure, compared to traditional single-step autologous transplant in salvage treatment of Hodgkin's and non-Hodgkin's lym-phoma [9, 10] , in multiple myeloma [11] [12] [13] and solid tumors [14] [15] [16] . We report herein the results of a pilot study of first-line consolidative tandem transplant in 36 poor-risk (2-3 factors of the Aa-IPI) patients with aggressive lymphoma.
Patients and methods

Patients
Between August 1995 and July 1997. 36 newly diagnosed consecutive patients with aggressive high-intermediate (two factors) and high risk (three factors) non-Hodgkin's lymphoma on the basis of the Aa-IPI were enrolled at four participating centers in a feasibility study of consolidative high-dose therapy with tandem peripheral blood stem cells transplants. Patients were under 60 years old and had biopsyconfirmed intermediate-or high-grade non-Hodgkin's lymphoma, according to the International Working Formulation. Histologic diagnosis was retrospectively converted from the Working Formulation to the World Health Organization classification [17] as reported in Table 1 . Patients with HIV positive serology were not eligible. All patients had normal baseline cardiac function (left ventricular ejection fraction more than 50%) Standardized staging evaluation was performed for each patient, including physical examination, biological parameters, imaging studies with at least a thoraco-abdominal computed tomog- Table I . Patient characteristics at diagnosis of the 36 enrolled patients and of the patients who received the first (« = 28) and the second transplant (n = 24). (46) 13 (54) 24 (100) 7 (29) 17 (71) 24 (100) 6 (25) 18 (75) 17 (71) 7 (29) 13 (54) 11 (46) raphy, and bone marrow biopsy. Patients provided informed consent, according to hospital regulations.
Induction treatment
All the patients received four cycles of the ACVBP regimen given in two week intervals, as in the LNH87 protocol [5] , with doxorubicin 75 mg/m 2 and cyclophosphamide 1200 nig/m 2 on day I, vindesine 2 mg/m 2 on days I and 5, bleomycin 10 mg on days I and 5, methylprednisolone 60 mg/m 2 on days I through 5, intrathecal methotrexate 15 mg on day 2. G-CSF was administered at a dosage of 5 ug/kg subcutaneously from day 6 to day 13 of the first three inductive cycles and until the end of leukapheresis, when performed after the fourth cycle (see below).
Tumor response criteria
Complete remission (CR) was defined as the disappearance of all sites of disease including normal bone marrow biopsy in the case of initial involvement. Additionally, patients with persistent CT abnormalities but regression of greater than 75% of the initial tumor were deemed to be in complete remission if in complete remission on all others parameters. Partial response (PR) was defined as a 50% to 75% reduction in tumor volume. Lesser response, progressive disease, and treatment-related death were considered as treatment failures. Tumor mass was assessed after the fourth cycle of ACVBP, and patients achieving CR or PR were deemed chemosensitive and allowed to proceed to HDT. Clinical restaging was carried out one month after the first autologous stem cell transplantation and at day 100 after the second autologous stem cell transplantation. Patients were then evaluated at 3-month intervals during the first two years of follow-up with full restaging twice a year, and then yearly or in the case of new symptoms.
Stem cell collection
Peripheral blood stem cells were collected by leukapheresis during the hematological recovery phase after the fourth cycle of ACVBP (n = 11) or after an additional mobilization regimen (n = 17) delivered two weeks after the last inductive cycle. This latter regimen included cyclophosphamide (4500 mg/m 2 ) and etoposide (450 mg/m 2 ) at dl in three divided doses by one hour infusion each. All the 17 patients received G-CSF at a dosage of 5 ug/kg subcutaneously from day 6 after the start of mobilization chemotherapy regimen to completion of leukaphereses.
At the time of hematological recovery, peripheral blood CD34+ cell counts were determined daily, and leukaphereses were started when they were superior to 20/ul. Leukaphereses were performed with continuous blood cell separators. The minimum number of CD34+ cells required for one and two planned HDT were 2.5 x 10 6 /kg and 5 x 10 6 /kg, respectively. No steady state collection with G-CSF alone or bone marrow harvest were envisaged if the number of CD34+ cells collected was insufficient.
Transplantation-conditioning regimens and tandem transplant modalities
Patients were eligible for HDT if they reached CR or PR after induction treatment and after PBSC had been collected. All patients undergoing HDT were required to have adequate pulmonary function (diffusion capacity greater than 50% of predicted) and liver function (serum bihrubin level less than 2 mg/dl).
First transplant: The first HDT was delivered 105 to 153 days after day I of the first inductive cycle (median: 128 days) with a BCVMitoxantrone regimen (carmustine 300 mg/m 2 i.v. once daily on day -4; cyclophosphamide 1500 mg/m 2 once daily i.v. for four consecutive days from day -7 to day -4 (total dose 6000 mg/m 2 ): VP16 250 mg/m i.v. once daily on day -7 to day -4; miloxantrone 45 mg/m 2 I.V once on day -8). Half of the stored PBSC were thawed and infused on day 0.
Second transplant: The second transplant was performed 46 to 82 days after the first reinfusion (median: 62 days) with a BCM (busulfancarboplatin-melphalan) conditioning regimen (busulfan 4 mg/kg p o. in divided doses daily (total 16 mg/kg) for 4 days from day -6 to day -3; carboplatin 400 mg/m 2 i.v. once daily from day -5 to day -3; mclphalan 140 mg/m 2 i.v. once on day -2). Stored PBSC were infused at day 0. The dosage of busulfan was decreased after the first patient of the series receiving a second transplant died from veno-occlusive disease (VOD). The 14 subsequent patients received busulfan at a dosage of 12 mg/kg and, since another patient died from VOD with the latter dosage, it was again decreased at 10 mg/kg in the remaining nine patients.
Supportive care
All patients had an indwelling central venous catheter and were housed in laminar air-flow rooms for the duration of aplasia. G-CSF after stem cell reinfusion, antiviral prophylaxis and prevention of VOD with heparin (1 mg/kg) were used according to each center policy Patients were treated with intravenous broad spectrum antibiotics when fever developed and absolute neutrophil count (ANC) was less than 0.5 x 10 9 /l. All patients received irradiated packed red blood cells and platelet products to maintain a hemoglobin level > 8 g/dl and a platelet count > 20 x 10 9 /l.
Toxicity evaluation criteria
The severity of side effects that occurred in the peritransplant periods were assessed according to the World Health Organization scoring system [18] and was defined as severe (grade 3) or life threatening (grade 4). VOD was diagnosed on the basis of clinical criteria with at least two of the following features present: jaundice (bihrubin > 2 mg/ dl), tender hepatomegaly and/or unexplained weight gain (> 5% from baseline)
Statistical methods
We compared times needed for hematological recovery, red blood cell (RBC) and platelets transfusions, and rates of toxic effects between the two transplants. As patients were submitted to tandem transplant, we considered each patient as his or her own control. Consequently all the comparisons of the measurement pairs were performed using the Wilcoxon signed rank test [19] . Differences were considered significant if the two-sided P-value was less than 0.05. The rates of event free survival and survival were estimated by the Kaplan-Meier method [20] . For this analysis, the end date was 15 August 2000. Event free survival was measured from the date of diagnosis to either disease progression, relapse, death from any cause or date of last follow-up when the end date was not reached. Overall survival was measured from the date of diagnosis to either death from any cause or last follow-up evaluation if the end date was not reached. Table 1 lists the pretreatment characteristics of these 36 high-intermediate (n -18) and high risk (n = 18) enrolled patients. There were 21 men and 15 women with 13 patients younger than 40 years of age. The vast majority (83%) of the patients had diffuse large B-cell lymphoma; all the patients presented both an extended stage of disease and an elevated LDH level. Twenty-six patients (72%) reached complete remission after induction treatment, 3 (8%) had partial response, 5 (14%) had no response or progressed during treatment, and 2 (6%) died following the first inductive cycle from toxicity. Twenty-eight of the 29 responder-patients received the CBV-Mitoxantrone conditioning regimen, since one patient developed a cerebral thrombophlebitis after the fourth cycle of ACVBP. Twenty four patients received the BCM conditioning regimen followed by the second transplant (see below). The main pretreatment characteristics of the transplanted patients are also indicated in Table 1 .
Results
Patient characteristics and response to induction treatment
Stem cell collection and reinfusion
The median number of leukaphereses was 2 (range: 1-6) and was identical whether the patients were collected after the fourth cycle of ACVBP (median: 2, range: 1-6) or after the combined mobilization regimen (median: 2, range: 1-4). The median number of CD34+ collected cells was 7.5 x 10 6 /kg (range: 3.1-37.5). The median number of CD34+ cells infused did not significantly differ between the first and second transplant, being 2.7 x 10 6 /kg (range: 0.5-10) and 3 x 10 6 /kg (range: 1-13), respectively. Table 2 summarizes the times for ANC and platelets recovery and transfusion requirements. Eight patients received G-CSF after the first stem cell reinfusion and seven patients after the second. All assessable patients reconstitued their white blood cells and platelets after the first transplant. After the second transplant, all the 24 patients achieved an ANC >0.5 x 10 9 /l, but two of them died (from VOD occurring at day 7 and from cerebral toxoplasmosis occurring at day 30) without achieving platelet recovery. It is noteworthy that the time to reach an ANC > 0.5 x 10 9 /l significantly differed between the first and the second HDT (P = 0.003). 
Hematological recovery after the two transplants
E.xtra-hematological toxicities during the two transplants
The main extra-hematological toxicities before day 100 are summarized in Table 3 . Three patients developed liver-biopsy confirmed VOD at day 7, day 10, and day 34 after the second transplant. The latter two patients died, at day 18 and at day 90, respectively. They had received busulfan in the conditioning regimen at a dosage of 16 mg/kg and 12 mg/kg, respectively, and had not received heparin prophylaxis. The third patient who received busulfan at a dosage of 10 mg/kg and heparin prophylaxis had a progressive clinical and biological improvement and portal hypertention resolved one year after the second transplant. All the patients developed neutropenic fever during both transplants. During the first transplant, seven patients had documented infections (two staphylococcus, two streptococcus, one escherichia coli and one listeria) and six during the second transplant (three staphylococcus, one escherichia coli, one klebsiellae and one pseudomonas). All fever and/or infections were successfully managed with broad-spectrum antibiotics. No death was attributed to infectious causes. Grade 3-4 mucositis requiring morphine occurred in 9 patients during the first transplant and in 12 during the second. To note, the duration of hospital stay after the second HDTwas significantly lower than after the first HDT (P = 0.03) ( Table 3) . Finally, no toxic death occurred after the first transplant and three toxic deaths (two from VOD and one from cerebral toxoplasmosis) occurred after the second transplant.
Response to the tandem transplants
Among the 28 patients who received the first transplant, 26 were considered in CR after this procedure, since two patients progressed early and died two and five months later. Twenty-four patients received the BCM conditioning regimen after the second transplant because two patients had insufficient stem collection. On day 100 after completion of the second transplantation procedure, 18 patients remained in CR as two patients had died from VOD and four patients had progressed.
Toxicity after day 100
Eight patients in complete remission developed an infection during the first year after the tandem transplant (five herpes zoster infections, two pulmonary infections related to mycobacterium and one cerebral toxoplasmosis). The latter patient died from this complication five months after the second transplant. One patient in early relapse developed a cytomegalovirus infection with retinitis and died from lymphoma progression nine months after the second transplant. Three patients developed congestive heart failure requiring treatment at 4, 7 and 36 months after the second transplant. One patient with initial pulmonary involvement developed pulmonary fibrosis possibly related to busulfan 18 months after the second transplant. Finally, one patient developed acute myeloid leukemia three and a half years after the second transplant. He is currently alive in complete remission six months after allogenic stem cell transplantation.
Outcome
Of the 29 patients responding to induction treatment, nine patients (among which six had received the second transplant) progressed in a median delay of nine months (range: 5 months to 16 months). Eight of them died within six months. One last patient who relapsed one year after the second transplant was treated with rituximab alone and is alive in a second CR, 46 months after this salvage treatment. At the time of analysis, 18 patients remained free of evolutive disease (17 in first CR and one in second CR) and 18 patients have died. The cause of deaths were lymphoma progression in 15 patients and toxicity following the second transplant in three patients (two from VOD and one from cerebral toxoplasmosis). Thus, with a median follow-up of 42 months, actuarial estimates of the three-year event free survival and overall survival rates for the entire group were 47% (95% CI: 31%-63%) ( Figure 1 ) and 50% (95% CI: 31%-63%) (Figure 2 ), respectively. To note, the three-year overall survival of the 28 patients who received at least the first transplant was 61% (95%> CI: 48%-86%) and that of the 24 patients who completed the tandem transplant procedure was 67% (95% CI: 43%-79%).
Discussion
To the best of our knowledge, this is the first prospective study of first line consolidative tandem transplant in poor risk (2-3 factors of the Aa-IPI) aggressive lymphoma. HDT as part of the initial treatment for aggressive lymphoma has been evaluated in several randomized trials and remains the subject of ongoing studies. To date, the results of three studies provide some evidence that first line HDT may benefit chemosensitive poorprognosis patients [3] [4] [5] . On behalf of the GELA, we recently published the final analysis of the LNH87-2 study [6] , which showed, with a median follow-up of eight years, that consolidation with the CBV regimen followed by autologous bone marrow transplantation gave a survival advantage over sequential chemotherapy (64% vs. 49%) in patients presenting with two or three risk factors of the Aa-IPI and in complete remission after induction treatment. In this series of higher risk patients, the overall response rate after four ACVBP inductive cycles was 74% (CR: 61%, PR: 13%), and it is noteworthy that the eight-year disease-free survival rate of patients assigned to single-step consolidative HDT was only 55%. Moreover, it appeared that among the latter, only 24% of the relapsing patients could be salvaged by HDT (i.e. a second transplant), as a result of chemoresistance. On this basis, we decided to explore the feasibility and potential benefit of first line consolidative tandem transplant with the objective of improving survival of higher risk patients in good response to induction by ACVBP regimen. The theoretic advantages of tandem transplant include exposure to potentially non-cross resistance drugs in rapid sequence and exposure of tumor to multiple effective agents at maximum-tolerated doses. To date, in the setting of hematological malignancies, little information has been published about procedure-related morbidity and outcome after first line tandem transplant in Hodgkin and non-Hodgkin's lymphoma [9, 10] , contrasting with the available data concerning patients with myeloma [11] [12] [13] .
To improve upon what can be achieved with one consolidative HDT, we used two different conditioning regimens, so as to exploit the theoretical benefit of any non-cross-resistant between successive treatments and to avoid cumulative toxicity of drugs. The first CBVmitoxantrone regimen was derived from the classical CBV (as used in the LNH87-2 study) and shown to give high complete response rate in refractory lymphoma [21] . The second conditioning regimen was based on carboplatin-melphalan in combination with a radiomimetic agent, busulfan. Twenty-four (86%) of our 28 eligible patients (i.e. in good response after induction and after collection of PBSC) did receive the planned procedure of tandem transplant. No toxic event related to the first transplant prevented from performing the second transplant from being performed, since the four patients who did not receive it either had insufficient stem cell collection (n -2) or early progression (/? = 2). Nevertheless, with this approach, we did not succeed, since the relapse rate of eligible patients remained high (32%). Moreover, treatment-related mortality was also high (11%), despite the fact that all the patients were treated in high accrual institutions of the GELA. Indeed, three of the 24 patients who received the second transplant developed hepatic VOD, which is an unusual rate (12%) of hepatic toxicity in the setting of autotransplant, and two of these patients died. This complication led us to further reduce the busulfan dosage from 16 to 10 mg/kg and should be taken into consideration when defining new experimental regimens. We also observed among the 24 patients a high rate of opportunistic infections usually encountered in immunocompromised patients (two mycobacterium infections, one cytomegalovirus retinitis and one lethal cerebral toxoplasmosis), which highly suggested the induction of a lymphocyte impairment by this tandem transplant procedure, just as it has been reported in patients receiving CD34-selected peripheral stem cells [22] or a T-cell depleted marrow transplantation [23] . Thus, in this series, although the overall response rate to induction treatment was 80%, which compares favorably with that observed in the LNH87-2 study (74%), survival rate of good-responder patients was not improved, since it was only 61% at the end of three years.
Our results of first line consolidative tandem transplant are difficult to compare with available studies of Hodgkin's disease and non-Hodgkin's lymphoma, since tandem transplant in the latter has been evaluated mostly in the setting of salvage therapy. Brice et al. recently reported [9] on the results of a prospective multicentric pilot study of feasibility and efficacy of tandem autotransplant in 43 patients with Hodgkin disease, of which 19 were considered as induction failures and 24 as very unfavorable relapses. Conditioning regimens were CBVMxt (mitoxantrone was delivered at 30 mg/m 2 ) for the first transplant and either melphalan-aracytine plus busulfan or total body irradiation (TBI) for the second. Four patients received busulfan at 16 mg/kg and two cases of grade 4 VOD were observed resulting in de-creased dosages of busulfan to 12 mg/kg in subsequent patients. The two-year survival for the entire group of 43 patients and for the 32 patients who did receive the two planned transplant were 65% and 74%, respectively, a result that was felt to be encouraging in this setting. Fitoussi et al. [10] reported on the results of a retrospective single institution study of consolidative tandem transplant in 24 patients with aggressive non-Hodgkin's lymphoma (n -15) and Hodgkin's disease (n = 9). Among the former, nine patients with two or three risk factors were transplanted as part of their initial therapy, and all the others were in early relapse. The first conditioning regimen was a BCV-mitoxantrone (mitoxantrone was delivered at 30 to 45 mg/m 2 ) and different regimens were used for the second transplant, including TBI in 11 patients and busulfan in 13 patients. VOD remained the major drawback since three cases were observed, two being fatal (one after TBI and one after busulfan). Nevertheless, results were considered encouraging since 14 (58%) of the 24 double-transplanted patients remained in continuous complete remission with a two-year survival rate of 80%.
Several reports have demonstrated the role of doseintensity in the treatment of myeloma patients and it has been shown in a randomized fashion that first-line HDT significantly improves overall survival [24] . Considering that promising results have been reported with tandem transplant [11. 12] , the French Myeloma Intergroup explored the potential benefit of this procedure when used as frontline therapy. Patients were randomized to receive either a single autologous transplant prepared with melphalan (140 mg/m 2 ) plus TBI or a double transplant, the first one prepared with melphalan (140 mg/m 2 ) and the second one with melphalan (140 mg/m 2 ) and TBI. The results of an intermediate analysis performed with a median follow-up of four years were recently reported [13] for 402 untreated patients under the age of 60 years. It appeared that median survival was similar for the two treatment arms (48 months and 54 months, respectively), although a benefit of tandem transplant was observed in a subgroup of patients surviving more than three years, a finding that remains to be confirmed with a longer follow-up.
In conclusion, the results of the present study did not lead us to further explore the use of tandem transplant in poor risk aggressive lymphoma. On the basis of the final analysis of the LNH87-2 study demonstrating the survival benefit of a single HDT and in order to improve upon what can be achieved with this one-step procedure in preventing relapses, the GELA designed a new trial incorporating rituximab. On the basis of encouraging data reported on tolerance and efficacy of rituximab in aggressive B-cell lymphoma [25, 26] , even after HDT [27] , we decided to explore the benefit of such a monoclonal antibody administered after transplant. Thus, in the ongoing LNH98-3 study, higher risk patients with diffuse large B-cell lymphoma in good response after induction treatment are receiving a single consolidative HDT and then are randomized to receive rituximab or not.
